The Efficacy of Fycompa (Perampanel) in Children With Epilepsy

Neurologic Disorder Clinical Trial

Official title:

Director of Child Neurology, Department of Pediatrics, National Taiwan University Hospital

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04608799
• Other study ID #: 201802018RIND
• Status: Completed
• Start date: January 1, 2018
• Est. completion date: March 19, 2020

Study information

• Verified date: October 2020
• Source: National Taiwan University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Fycompa (Perampanel), a new anti-epileptic drug that uses a new mechanism-AMPA receptor antagonist. Its initial indication is for local or generalized epilepsy in children and adults over 12 years old, but its effectiveness in the treatment of epilepsy in children At present, more evidence is still needed. We will study the effectiveness of Fycompa (Perampanel) in the treatment of epilepsy in children under the age of 18. It is expected that the clinical use of Fycompa (Parampanel) in Taiwan will be able to analyze and study the effectiveness of the clinical use of Fycompa (Parampanel) in the treatment of epilepsy in children, and compare it with foreign reports.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 38
• Est. completion date: March 19, 2020
• Est. primary completion date: March 19, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 18 Years

Eligibility

Inclusion Criteria:

• Patients under 18 years of age suffering from epilepsy

• Patients who are taking Paraampanel

Exclusion Criteria:

• Patients who are not in the above age groups and who are not using parampanel

Related Conditions & MeSH terms

• Nervous System Diseases
• Neurologic Disorder

Intervention

Drug:
• Perampanel
Efficacy of epilepsy drugs

Locations

Country	Name	City	State
Taiwan	National Taiwan University Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The efficacy of perampanel in young children with drug-resistant epilepsy	Because the current clinical research data on the use of Fycompa (perampanel) in children for the treatment of epilepsy is still insufficient, the purpose of this research is to review the efficacy of this drug in the treatment of children with epilepsy in our hospital in the past, so as to facilitate the future clinical treatment of children with epilepsy. Children have the possibility of therapeutic reference.	17 years